Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Sandoz"

21 News Found

Caplin Steriles gets USFDA approval for Difluprednate Ophthalmic emulsion
Drug Approval | December 17, 2024

Caplin Steriles gets USFDA approval for Difluprednate Ophthalmic emulsion

Difluprednate Ophthalmic Emulsion, 0.05% is a topical corticosteroid that is indicated in the treatment of inflammation and pain associated with ocular surgery


Glenmark Pharmaceuticals USA launches Travoprost Ophthalmic Solution USP, 0.004%
News | November 28, 2024

Glenmark Pharmaceuticals USA launches Travoprost Ophthalmic Solution USP, 0.004%

Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz


Natco Pharma appoints Madhava Rao Karicherla as Associate VP – Formulation Research & Development
People | November 16, 2024

Natco Pharma appoints Madhava Rao Karicherla as Associate VP – Formulation Research & Development

He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali and Bachelor of Pharmacy from Osmania University


Alembic receives USFDA final approval for Nelarabine Injection, 250 mg/50 mL
Drug Approval | August 03, 2024

Alembic receives USFDA final approval for Nelarabine Injection, 250 mg/50 mL

Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia


Lupin receives USFDA approval for travoprost ophthalmic solution
Drug Approval | May 07, 2024

Lupin receives USFDA approval for travoprost ophthalmic solution

Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.


Cenexi appoints Jim McPherson as CEO
People | September 20, 2023

Cenexi appoints Jim McPherson as CEO

Prior to this, Jim held leadership positions at several companies, including Centrient Pharmaceuticals, Leo Pharmaceuticals, Sandoz, Xellia, and GSK


Novartis maintains growth momentum; Confirms FY’22 Group guidance
News | October 26, 2022

Novartis maintains growth momentum; Confirms FY’22 Group guidance

Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.


Novartis unveils new focused strategy
News | September 27, 2022

Novartis unveils new focused strategy

Transformation to pure-play Innovative Medicines company nears completion


PHARMAP 2022 concludes with productive networking of pharma leaders
News | June 28, 2022

PHARMAP 2022 concludes with productive networking of pharma leaders

The Congress was held on June, 20-21, 2022 in Berlin, Germany


PHARMAP 2022 to discuss contemporary issues
News | March 25, 2022

PHARMAP 2022 to discuss contemporary issues

The Congress gathers pharmaceutical companies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies